Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update

Autolus Therapeutics plc (NASDAQ:AUTL) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 7,680,000 shares, an increase of 22.1% from the November 30th total of 6,290,000 shares. Based on an average daily volume of 1,750,000 shares, the short-interest ratio is presently 4.4 days.

Analyst Ratings Changes

AUTL has been the subject of several research analyst reports. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Finally, The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL traded down $0.04 during midday trading on Friday, hitting $2.26. The company had a trading volume of 1,720,520 shares, compared to its average volume of 1,495,747. Autolus Therapeutics has a twelve month low of $2.07 and a twelve month high of $7.45. The stock has a market cap of $601.37 million, a price-to-earnings ratio of -1.87 and a beta of 1.98. The business’s 50-day simple moving average is $3.18 and its 200-day simple moving average is $3.71.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the firm earned ($0.26) EPS. As a group, sell-side analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. Wellington Management Group LLP lifted its stake in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares during the period. FMR LLC raised its holdings in Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after purchasing an additional 5,478,706 shares during the last quarter. Great Point Partners LLC boosted its position in Autolus Therapeutics by 195.0% during the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after purchasing an additional 2,275,000 shares in the last quarter. Armistice Capital LLC grew its holdings in Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after purchasing an additional 1,578,000 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Autolus Therapeutics by 74.5% in the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock valued at $8,810,000 after buying an additional 1,080,897 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.